Trial topic
Omega-3 and childhood cognitive function

Trial center
The Faculty of Public Health, Mahidol University, Thailand

Objective
To evaluate the effect of Bright Kids® supplementation on cognitive function in children

Sample
School-aged children (6-12 years) willing to participate, with concurrent informed parental consent

Methods
Clinical intervention followed a three-arm, double-blind, randomised design. Participants (n = 120) were recruited and allocated to receive either placebo or the test product over a 3-month period. Efficacy was assessed by changes in their responses to tests for memory and attention span, based on non-invasive measurement of brain electrical activity.

Results
This study is registered with the Thai Clinical Trials Register and is currently being reviewed for publication

Trial topic

Supporting healthy glucose metabolism

Trial center

The Faculty of Public Health, Mahidol University, Thailand

Objective

To investigate the efficacy of Aquielle in maintaining healthy glucose status, cardiovascular health and antioxidant status.

Sample

110 Thai subjects (aged 20-70) were included.

Methods

A randomised, double-blind, placebo-controlled study was conducted. Patients were divided into 2 groups, and each group was administered either Aquielle or placebo for 3 consecutive months (2 tablets daily).

Results

The outcomes of this trial have been published in the Journal of Natural Products. Aquielle use resulted in a beneficial effect on glucose balance, blood lipids and oxidative stress levels.

Trial topic

Dietary iron deficiency in pregnancy

Trial center

The Faculty of Public Health, Mahidol University, Thailand

Objective

To evaluate the effectiveness of ferrous bisglycinate in IronUp® for improving dietary iron deficiency in pregnant women

Sample

Pregnant women with dietary iron deficiency (20-40 years of age, 12-16 weeks)

Methods

Participants will be divided randomly into 2 groups and each will receive either IronUp® (1 capsule daily) or ferrous fumarate (1 tablet daily) for 6 months. Parameters such as haematological status, iron absorption, side effects, quality of life and general wellbeing will be monitored during and after the trial to analyse treatment effects

Results

The outcomes of this trial have been published in Nutrients. IronUp® resulted in improvements in iron absorption, iron status and blood cell counts, with lower digestive side effects than a control supplement with iron fumarate, with a 66% lower dose of iron than the control.

Trial topic

Articular & arthritic pain

Trial organization

ClinMed Pharma, Poland

Objective

To assess the efficacy of Tregocel® in addition to standard of care treatment in patients with symptomatic joint aches and pains

Sample

Individuals from 40 years of age, with clinically evaluated joint aches and pains

Methods

A total of 150 participants were recruited and assigned Tregocel® (2 tablets/day) orally for 36 weeks. Efficacy was assessed by changes in ambulatory mobility as well as perceived pain, stiffness and difficulty with daily tasks. Safety was assessed by concurrent monitoring of haematological and urine parameters

Results

Tregocel® resulted in progressive reductions in pain, stiffness, mobilty and joint flexibility, an improved endurance during walking a reduced reliance on presription pain killers. The outcomes of this trial have been reported in 3 different European medical journals:

1. https://www.hindawi.com/journals/aorth/2021/5589597/
2. https://wiadlek.pl/wp-content/uploads/archive/2021/WLek202108134.pdf
3. https://wiadlek.pl/wp-content/uploads/archive/2021/WLek202109119.pdf

Trial topic

Relieving symptoms of occasional episodes of gout

Trial center

National Hospital for Traditional Medicine in Hanoi, Vietnam

Objective

To evaluate the safety, efficacy, and tolerability of GoutFighter for relieving symptoms of occasional episodes of gout symptoms

Sample

Adult patients were eligible to be included if they had a history of chronic gout

Methods

Clinical intervention followed a single-arm, open-label design. Participants (n = 35) received 4 tablets of GoutFighter daily over a 45-day period. Efficacy was assessed by changes in pain, swelling and blood uric acid levels, with concurrent safety and tolerability assessments

Results

GoutFighter usage resulted in statistically signifant reductions in joint pain and uric acid levels. The outcomes of this trial have been published in the Journal of Integrative & Complementary Medicine

Trial topic

Sperm health

Trial center

National Institute of Complementary Medicine (NICM) hosted by Western Sydney University in Australia

Objective

To assess the effect of Hominax, a product consisting of 15 active ingredients, including antioxidants, herbs, nutrients and vitamins, on the sperm health of men

Sample

Healthy men aged between 20-60 years old, clinically assessed for sperm health status

Methods

Clinical intervention followed an open-label, single-arm design. Participants received 2 capsules of Hominax each day for 24 weeks. The primary outcome measures included changes in sperm concentration, motility and morphology. Secondary outcome measures included the number of confirmed pregnancy as well as changes in lipid peroxidation of seminal plasma and sperm, sperm DNA fragmentation, semen volume, semen pH and blood homocysteine levels. In addition, changes in serum micronutrient status of vitamin B12, zinc, folate and adverse events were monitored throughouth the trial.

Results

This study is registered with the Australian New Zealand Clinical Trials Register and has finished recruiting patients

Trial topic

Premenopausal and menopausal symptoms

Trial center

Medical University of Hanoi, Vietnam

Objective

To assess the efficacy and safety of ^PMH-Regulator® for improving premenopausal and menopausal symptoms

Sample

Healthy premenopausal and menopausal women

Methods

A total of 77 participants were administered 1 capsule of ^PMH-Regulator® on a daily basis for 3 consecutive months

Results

After the treatment, fewer women experienced vasomotor symptoms (i.e. hot flushes, night sweats, chills and palpitations) and neurological symptoms (i.e. headaches, concentration difficulties). In addition, improvements in urogenital-vaginal symptoms (i.e. vaginal dryness, pain during intercourse, urogenital infection) were observed following treatment and ^PMH-Regulator® was well tolerated

Conclusion

^PMH-Regulator® is effective and safe for decreasing menopausal symptoms. For more information about the trial, please contact us here

Trial topic

Sexual health

Trial center

Two studies were conducted in Vietnam, at the Obstetrics & Gynaecology Hospital, Branch No. 4, of Ho Chi Minh City University of Medicines and Pharmaceuticals

Objective

To study the effects of RED-LIFE for MEN® and RED-LIFE for WOMEN® on the sexual wellbeing of males and females

Sample

Healthy males and females aged ≥ 18 years who are in stable heterosexual relationships, but without their partner in the concurrent study, with self-reported sexual dissatisfaction

Methods

We conducted two single-arm, open-label trials on males (study 1) and females (study 2) alike. Males and females consumed 2 tablets, twice per day, of either RED-LIFE for MEN® or RED-LIFE for WOMEN® respectively, over a 4-week period. Changes were assessed by the International Index of Erectile Function (IIEF) and the Female Sexual Function Index (FSFI)

Results

In both studies, improvements were observed in measures of sexual health, performance and satisfaction, and 4 weeks of treatment showed better improvements than 2 weeks treatments

Conclusion

Clinically relevant doses of RED-LIFE for MEN® and RED-LIFE for WOMEN® elicited favourable effects on male and female sexual health, performance and satisfaction. For more information about the trial, please contact us here

Trial topic

Post-menopausal symptoms and skin health

Trial center

Department of Nutrition, Faculty of Public Health, Mahidol University, Thailand

Objective

To determine the effect of “Belle Dame (Supporting Womens’ Health)” on menopausal symptoms, hormonal changes and facial skin health.

Sample

Women aged 45-60 with menopausal symptoms and signs of skin aging.

Methods

Women were randomized to receive the test product or a placebo capsule for 12 week. During this time, investigators evaluated menopausal symptoms (MRS), blood reproductive hormones, facial dermatology, safety assessments (basic health indicators & blood testing including) and blood markers of oxidative stress, inflammation, cardiovascular and liver health.

Results

Compared to the placebo, use of the test product resulted in improvements in some menopause symptoms, reductions in inflammation, oxidative stress status and improvements in skin integrity. Full details of the trial have been published in the following journals:

1. Journal of Dietary Supplements
2. Journal of Cosmetic Dermatology